Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer

Muscogiuri G, Del Vecchio G, Colangeli L, et al.

Internal and emergency medicine, 2026

Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss

Rahman E, Michon A, Rao P, et al.

Aesthetic plastic surgery, 2026

GLP-1 medications: use and interest in a representative survey of Finns

Jallinoja PT, Pietiläinen KH, Chang VW

International journal of obesity (2005), 2026

Brain Neuromodulation via Endoscopic Gastric Implant Improves Glycemic Control in Insulin-Dependent Type-2 Diabetes: First-in-Human Feasibility and Autonomic Response Study

Cigaina V, Saggioro A, Fabris P, et al.

Journal of laparoendoscopic & advanced surgical techniques. Part A, 2026;:10926429261468981

Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer’s disease

Vear A, Olsen SA, Lange ECH, et al.

Cell reports. Medicine, 2026;:102906

Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses

Kanu C, Shinde S, Falcon B, et al.

Sleep, 2026

Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis

Zhou XY, Deng CH, Zhong JY, et al.

Nutrition, metabolism, and cardiovascular diseases : NMCD, 2026;:104859

Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Heart Failure Outcomes: A Scoping Review of Contemporary Randomized Controlled Trials

Patel J, Patel D, Pino M

Cureus, 2026;18(7):e112239

Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study

Ambika Gopalakrishnan U, Joshi A, Kumar H, et al.

Diabetes, obesity & metabolism, 2026

Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series

Shah T, Dougherty C, Ailani J, et al.

Headache, 2026

Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR) : a pilot randomized controlled trial

Lau LCM, Lui TWD, Wen C, et al.

Bone & joint open, 2026;7(7):861-870

GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study

Park J, Kim JH, Kim YS, et al.

Diabetes, obesity & metabolism, 2026

A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice

Zhang Y, Zhu B, Peng B, et al.

Diabetes, obesity & metabolism, 2026

Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

Berry SA, Goodman IR, McNally E, et al.

Diabetes, obesity & metabolism, 2026

Comment on ‘The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies’

Bao J, Wang M

Diabetes, obesity & metabolism, 2026

Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis

Silva JPMRJ, Nogueira BV, Sartori DL, et al.

Diabetes, obesity & metabolism, 2026

Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials

Ukkonen M, Kivivuori A, Starckjohann P, et al.

Diabetes, obesity & metabolism, 2026

Correction to: “Atypical retrobulbar optic neuropathy after semaglutide escalation”

JCEM case reports, 2026;4(8):luag179

Correction: Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study

Hirotsu T, Taniguchi K, Nishimura R

Frontiers in clinical diabetes and healthcare, 2026;7:1914250

Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

Galasso M, Verde L, Patrone R, et al.

Frontiers in endocrinology, 2026;17:1855886